Veeco Instruments Inc. (VECO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Veeco Instruments Inc. is a manufacturer of semiconductor process equipment, including ion beam, laser annealing, lithography, MOCVD, CVD, and single wafer wet processing technologies. The company operates as a single reportable segment serving four end-markets: Semiconductor, Compound Semiconductor, Data Storage, and Scientific & Other.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales | $184.8M | $177.4M | $535.2M | $492.5M |
| Gross Profit | $79.2M | $76.9M | $230.0M | $206.4M |
| Gross Margin | 43% | 43% | 43% | 42% |
| Operating Income | $24.3M | $22.3M | $63.1M | $45.8M |
| Net Income | $22.0M | $24.6M | $58.7M | ($52.0M) |
| Diluted EPS | $0.36 | $0.42 | $0.97 | ($0.98) |
| Cash & Equivalents | $163.2M | $158.8M | Short-term investments: $157.5M | |
| Total Debt (Carrying Value) | $275.9M | Includes $26.5M (2025), $25.0M (2027), $230.0M (2029) Notes | ||
| Operating Cash Flow (9M) | $35.4M | $32.2M |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 net sales increased 4% year-over-year, driven primarily by a 26% increase in Semiconductor revenue ($124.1M). This growth was partially offset by declines in Compound Semiconductor (-39%) and Scientific & Other (-37%).
- Profitability: Operating income increased 9% to $24.3M. Net income decreased 11% to $22.0M compared to Q3 2023, largely due to a higher effective tax rate (10.98% expense vs. 9.17% benefit in prior year) and the absence of a discrete tax benefit from R&D credits recognized in the prior year.
- Non-Operating Items: The 9M 2023 period included a $97.1M loss on the extinguishment of convertible notes, which significantly impacted the prior year's net loss. No such loss occurred in 2024.
- Geographic Shifts: Sales in China increased 34% in Q3, while EMEA sales declined 62%.
Guidance, Outlook, and Risks
- Semiconductor Outlook: Management expects year-over-year growth in Semiconductor revenue for 2024, driven by AI, High-Bandwidth Memory (HBM), and advanced logic nodes. However, engagement with customers in China has moderated, suggesting a normalization of revenue from that region in 2025.
- Market-Specific Outlook:
- Compound Semiconductor: Expected to be down in 2024 due to a slowdown in EV adoption affecting SiC demand.
- Data Storage: Expected to be up in 2024 due to backlog execution, but a ~$70M revenue reduction is anticipated in 2025 as customers do not expand capacity.
- Scientific & Other: Expected to be flat to down in 2024.
- Liquidity: The company increased its revolving credit facility from $150M to $225M in August 2024. No amounts were drawn as of September 30, 2024.
- Risks: Key risks include global trade policy changes (specifically U.S.-China disputes), export control restrictions, cyclicality of the semiconductor industry, and reliance on a concentrated customer base.
Investor Verification Checklist
- China Revenue Sustainability: Verify the extent of the "moderation" in China engagement and its potential impact on 2025 guidance, given China represented 30% of Q3 sales.
- Convertible Note Conversion: Monitor the 2025 and 2027 Notes, which are currently convertible by holders until December 31, 2024, due to stock price performance exceeding 130% of conversion prices.
- Data Storage Backlog: Confirm the execution of planned shipments in the Data Storage backlog to meet 2024 revenue targets before the anticipated 2025 decline.
- Epiluvac Earn-out: Track the contingent consideration liability ($17.7M) related to the Epiluvac acquisition, as changes in estimates continue to impact operating income.
- Inventory Levels: Review inventory trends ($242.1M) relative to sales to ensure no obsolescence risks arise from the cyclical downturn in Compound Semiconductor and Data Storage markets.